RU95121693A - Производные глицерина, средство для доставки лекарств (dds) и фармацевтическая композиция - Google Patents

Производные глицерина, средство для доставки лекарств (dds) и фармацевтическая композиция

Info

Publication number
RU95121693A
RU95121693A RU95121693/04A RU95121693A RU95121693A RU 95121693 A RU95121693 A RU 95121693A RU 95121693/04 A RU95121693/04 A RU 95121693/04A RU 95121693 A RU95121693 A RU 95121693A RU 95121693 A RU95121693 A RU 95121693A
Authority
RU
Russia
Prior art keywords
dds
drug delivery
phospholipid
carbamoyl
glycerol
Prior art date
Application number
RU95121693/04A
Other languages
English (en)
Other versions
RU2123492C1 (ru
Inventor
Яно Юнити
Охги Тадааки
Original Assignee
Ниппон Синяку Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ниппон Синяку Ко., Лтд. filed Critical Ниппон Синяку Ко., Лтд.
Priority claimed from PCT/JP1994/000237 external-priority patent/WO1994019314A1/ja
Publication of RU95121693A publication Critical patent/RU95121693A/ru
Application granted granted Critical
Publication of RU2123492C1 publication Critical patent/RU2123492C1/ru

Links

Claims (12)

1. Производные глицерина общей формулы I
Figure 00000001

где R1 и R2 - не одинаковы и каждый представляет ОY или -А(СН2)n-Е;
n представляет целое число от 0 до 4;
Е представляет пирролидино, пиперидино, замещенный или незамещенный пиперазино, морфолино, замещенный или незамещенный гуанидино или
Figure 00000002

где R3 и R4 - одинаковы или различны и каждый представляет водород, низший С1-C4-алкил, гидроксинизший-С1-C4-алкил или моно- или ди-(низший) алкиламиноалкил-С2-C8;
А представляет следующие значения:
Figure 00000003

Figure 00000004

R и Y - одинаковы или различны и каждый представляет насыщенную или ненасыщенную алифатическую углеводородную группу, содержащую 10 - 30 атомов углерода, или насыщенный или ненасыщенный остаток жирной кислоты, содержащий от 10 до 30 атомов углерода, однако при этом исключаются соединения, в которых А представляет указанные ранее
Figure 00000005
а n = 1.
2. Производные глицерина общей формулы I' по п. 1
Figure 00000006

где R11 и R21 - одинаковы или различны и каждый представляет омил или омоил;
D представляет -CH2- или NH-;
R30 и R40 - одинаковы или различны и каждый представляет метил или этил.
3. Соединение по п. 1, отличающееся тем, что его выбирают из группы, состоящей из 3-O-(4-диметиламинобутаноил)- 1,2-O-диолеилглицерина, 3-O-(2-диметиламиноэтил)карбамоил-1,2-O- диолеилглицерина, 3-O-(2-диэтиламиноэтил)карбамоил-1,2-O-диолеилглицерина и 2-O-(2-диэтиламиноэтил)карбамоил-1,3-O-диолеоилглицерина.
4. Средство для доставки лекарства (DDS), отличающееся тем, что содержит соединение общей формулы I и фосфолипид в качестве основных компонентов.
5. Средство для доставки лекарств (DDS) по п. 4, отличающееся тем, что содержит соединение общей формулы I' и фосфолипид в качестве основных компонентов.
6. Средство для доставки лекарств (DDS) по п. 4, отличающееся тем, что содержит соединение, выбранное из группы, состоящей из 3-O-(4- диметиламинобутаноил)-1,2-O-диолеилглицерина, 3-O-(2-диметиламиноэтил)карбамоил-1,2-O-диолеилглицерина, 3-O-(2-диэтиламиноэтил)карбамоил-1,2-O-диолеилглицерина и 2-O-(2-диэтиламиноэтил)карбамоил-1,3-O-диолеоилглицерина и фосфолипид в качестве основных компонентов.
7. Средство для доставки лекарств (DDS) по п. 4, отличающееся тем, что указанный фосфолипид является фосфатидилэтаноламином или фосфатидилхолином.
8. Средство для доставки лекарств (DDS) по п. 5, отличающееся тем, что указанный фосфолипид является фосфатидилэтаноламином или фосфатидилхолином.
9. Средство для доставки лекарств (DDS) по п. 6, отличающееся тем, что указанный фосфолипид является фосфатидилэтаноламином или фосфатидилхолином.
10. Фармацевтическая композиция, отличающаяся тем, что содержит средство, заявленное в любом из пп. 4 - 9, и физиологически активное вещество.
11. Фармацевтическая композиция по п. 10, отличающаяся тем, что указанное физиологически активное вещество является двухнитевой РНК.
12. Фармацевтическая композиция по п. 10, отличающаяся тем, что указанное физиологически активное вещество является двухнитевой РНК, состоящей из сополимера полинозиновой кислоты и цитидиловой кислоты, содержащего одно звено 4-тиоурудиловой кислоты на каждые 20 звеньев цитидиловой кислоты и полное распределение по размерам молекул в интервале около 50 - 10000 оснований.
RU95121693A 1993-02-19 1994-02-17 Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция RU2123492C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPHEI-5/054,939 1993-02-19
JP5493993 1993-02-19
PCT/JP1994/000237 WO1994019314A1 (en) 1993-02-19 1994-02-17 Glycerol derivative, device and pharmaceutical composition

Publications (2)

Publication Number Publication Date
RU95121693A true RU95121693A (ru) 1997-09-27
RU2123492C1 RU2123492C1 (ru) 1998-12-20

Family

ID=12984615

Family Applications (2)

Application Number Title Priority Date Filing Date
RU95121696/14A RU2143903C1 (ru) 1993-02-19 1994-02-17 Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты
RU95121693A RU2123492C1 (ru) 1993-02-19 1994-02-17 Производные глицерина, средство для доставки физиологически активного вещества и фармацевтическая композиция

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU95121696/14A RU2143903C1 (ru) 1993-02-19 1994-02-17 Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты

Country Status (11)

Country Link
US (2) US6020317A (ru)
EP (2) EP0685457B1 (ru)
JP (1) JP3189279B2 (ru)
KR (2) KR100283601B1 (ru)
AT (2) ATE187713T1 (ru)
AU (2) AU6044994A (ru)
CA (2) CA2156289C (ru)
DE (2) DE69424406T2 (ru)
ES (1) ES2142934T3 (ru)
RU (2) RU2143903C1 (ru)
WO (2) WO1994019314A1 (ru)

Families Citing this family (284)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11508231A (ja) * 1995-05-26 1999-07-21 ソマティックス セラピー コーポレイション 安定な脂質/核酸複合体を含む送達ビヒクル
CA2223179A1 (en) 1995-06-07 1996-12-19 Bob Dale Brown Phosphonic acid-based cationic lipids
JPH11507352A (ja) * 1995-06-07 1999-06-29 ジンタ・インコーポレイテッド 新規カルバメート基本カチオン性脂質
AU734968B2 (en) * 1996-07-22 2001-06-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Vectors for inhibiting HIV and tumor growth
FR2759367A1 (fr) * 1997-02-10 1998-08-14 Transgene Sa Glycerolipides cationiques et complexes de glycerolipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2759382A1 (fr) * 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
TW524693B (en) * 1997-10-16 2003-03-21 Nippon Shinyaku Co Ltd Cancer cell nuclease activator
MY134896A (en) 1998-03-24 2007-12-31 Nippon Shinyaku Co Ltd Therapeutic agent for hepatitis
US6043390A (en) * 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
EP1469009A2 (en) * 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
AU753270B2 (en) * 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
KR100644172B1 (ko) * 1998-05-25 2006-11-10 니뽄 신야쿠 가부시키가이샤 핵산 함유 복합체 제제의 제조 방법
DE60021354T2 (de) * 1999-02-15 2006-04-27 Nippon Shinyaku Co., Ltd. Polynukleotide mit gekürzter kette und verfahren zu ihrer herstellung
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
WO2001042200A1 (en) * 1999-12-10 2001-06-14 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
US20030134420A1 (en) * 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
AU2002246541A1 (en) * 2000-11-28 2002-08-06 Promega Corporation Rna polymers and uses thereof
GB0106041D0 (en) * 2001-03-12 2001-05-02 Cancer Res Ventures Ltd Lipids and liposomes
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ566396A (en) 2001-10-09 2009-07-31 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
WO2003057916A2 (en) 2002-01-09 2003-07-17 Riken Cancer profiles
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US20060193905A1 (en) * 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
EP2330194A3 (en) * 2002-09-13 2011-10-12 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US7229976B2 (en) 2002-09-26 2007-06-12 Isis Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
PT1569695E (pt) 2002-11-13 2013-07-16 Genzyme Corp Modulação anti-sentido da expressão de apolipoproteína
WO2004044181A2 (en) 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
JP4623426B2 (ja) * 2003-05-30 2011-02-02 日本新薬株式会社 オリゴ核酸担持複合体、当該複合体を含有する医薬組成物
JP4505749B2 (ja) * 2003-05-30 2010-07-21 日本新薬株式会社 Bcl−2の発現抑制をするオリゴ二本鎖RNAとそれを含有する医薬組成物
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
WO2005041870A2 (en) * 2003-10-24 2005-05-12 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US7947659B2 (en) * 2004-03-12 2011-05-24 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
EP1742958B1 (en) 2004-03-15 2017-05-17 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US8815599B2 (en) * 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7498315B2 (en) * 2004-06-01 2009-03-03 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
JP5087924B2 (ja) * 2004-08-26 2012-12-05 日本新薬株式会社 ガラクトース誘導体、薬物担体及び医薬組成物
US7973084B2 (en) 2005-04-28 2011-07-05 Postech Academy-Industrial Foundation Molecular transporters based on alditol or inositol and processes for the preparation thereof
KR100699279B1 (ko) * 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
EP1886688A4 (en) 2005-05-30 2013-01-09 Nippon Shinyaku Co Ltd METHOD FOR PRODUCING PREPARATION OF A NUCLEIC ACID-CONTAINING COMPLEX
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
KR100789323B1 (ko) * 2005-07-20 2007-12-28 주식회사 엔지켐 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체
EP2612870A1 (en) 2005-09-12 2013-07-10 The Regents of the University of Michigan Recurrent gene fusions in prostate cancer
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
US7723112B2 (en) 2005-10-31 2010-05-25 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1951737A4 (en) * 2005-11-01 2009-07-01 Alnylam Pharmaceuticals Inc INHIBITION OF INFLUENZA VIRUS REPLICATION BY RNA INTERFERENCE
WO2007064857A2 (en) 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Amphoteric liposome formulation
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
CA2638797A1 (en) * 2006-03-01 2007-09-07 Nippon Shinyaku Co., Ltd. Galactose derivative, drug carrier and medicinal composition
KR101362681B1 (ko) 2006-03-31 2014-02-13 알닐람 파마슈티칼스 인코포레이티드 Eg5 유전자의 발현을 억제하는 조성물 및 억제 방법
EP2013222B1 (en) * 2006-04-28 2013-02-13 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
BRPI0712034A2 (pt) 2006-05-19 2012-01-10 Alnylam Pharmaceuticals Inc modulação de rnai de aha e usos terapêuticos do mesmo
US7888498B2 (en) * 2006-05-22 2011-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
EP2032652A4 (en) * 2006-06-05 2011-08-17 Massachusetts Inst Technology NETWORKED DEVELOPABLE POLYMERS AND ITS USE
WO2008011561A2 (en) * 2006-07-21 2008-01-24 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
US20080261216A1 (en) * 2006-09-08 2008-10-23 The Regents Of The University Of Michigan HERV Group II Viruses In Lymphoma And Cancer
WO2008045952A2 (en) * 2006-10-10 2008-04-17 The Regents Of The University Of Michigan Photoreceptor precursor cells
US8048998B2 (en) * 2007-01-19 2011-11-01 Exiqon A/S Mediated cellular delivery of LNA oligonucleotides
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008096690A1 (ja) 2007-02-05 2008-08-14 Nippon Shinyaku Co., Ltd. ポリエチレングリコール誘導体
WO2008109806A2 (en) * 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
EP2905336A1 (en) 2007-03-29 2015-08-12 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of a gene from the ebola
KR20100029079A (ko) * 2007-05-15 2010-03-15 헬리콘 테라퓨틱스 인코퍼레이티드 Gpr12의 저해로 인지 질환을 치료하는 방법
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
PL3009148T3 (pl) 2007-07-02 2019-03-29 Oncomed Pharmaceuticals, Inc. Kompozycje oraz sposoby leczenia i diagnozowania nowotworu
CA2814246A1 (en) 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and erg family gene fusions in prostate cancer
US8865178B2 (en) 2007-07-17 2014-10-21 University Of Massachusetts Compositions and methods for wound healing
US8084057B2 (en) 2007-07-17 2011-12-27 University Of Massachusetts Compositions and methods for wound healing
EP2179292B1 (en) 2007-08-16 2012-11-28 The Regents of the University of Michigan Metabolomic profiling of prostate cancer
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
AU2008335202A1 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Factor VII gene
WO2009086558A1 (en) * 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
WO2009100351A2 (en) * 2008-02-08 2009-08-13 Alnylam Pharmaceuticals, Inc. Delivery of rnai constructs to oligodendrocytes
AU2009221775B2 (en) 2008-03-05 2015-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2009129387A2 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009129385A1 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
CA2727428A1 (en) 2008-06-19 2009-12-23 Nippon Shinyaku Co., Ltd. Drug carrier
US8252762B2 (en) 2008-08-25 2012-08-28 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2690175B1 (en) 2008-09-02 2016-12-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression
EP3109321B1 (en) 2008-09-25 2019-05-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
RU2579897C2 (ru) 2008-09-26 2016-04-10 Онкомед Фармасьютикалс, Инк. Агенты, связывающие рецептор "frizzled", и их применение
CA2742954C (en) 2008-11-07 2018-07-10 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US8846012B2 (en) * 2008-12-22 2014-09-30 Pola Chemical Industries Inc. Melanin production inhibitor
JP2012514475A (ja) 2009-01-09 2012-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌における再現性の遺伝子融合物
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2756845B1 (en) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
US20100272824A1 (en) * 2009-04-16 2010-10-28 The Texas A&M University System Compositions and methods for preventing and monitoring disease
WO2010132821A2 (en) 2009-05-14 2010-11-18 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders
WO2010141630A1 (en) 2009-06-03 2010-12-09 University Of Southern California Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
EP2823810B9 (en) 2009-07-09 2019-10-30 Novosom Verwaltungs GmbH Amphoteric liposomes comprising imino lipids
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011025540A1 (en) 2009-08-28 2011-03-03 Bellweather Farms Chemical induction of lactation
EP2490699A1 (en) 2009-10-20 2012-08-29 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
US9125931B2 (en) 2010-04-06 2015-09-08 Massachusetts Institute Of Technology Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
EP4385568A2 (en) 2010-04-06 2024-06-19 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
JP6081910B2 (ja) 2010-06-02 2017-02-15 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. 肝線維症治療用組成物および肝線維症の治療法
IL300109A (en) * 2010-06-03 2023-03-01 Alnylam Pharmaceuticals Inc Biodegradable lipids for the transfer of active substances
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
US9127275B2 (en) 2010-12-10 2015-09-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
WO2012078967A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (epo) production
JP6177692B2 (ja) 2011-02-02 2017-08-09 エクスカリアード・ファーマシューティカルズ,インク 結合組織増殖因子(ctgf)をターゲティングするアンチセンス化合物を用いた、ケロイドまたは肥厚性瘢痕の治療法
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
PL2691443T3 (pl) 2011-03-28 2021-08-30 Massachusetts Institute Of Technology Sprzężone lipomery i ich zastosowania
KR102481317B1 (ko) 2011-03-29 2022-12-26 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
CN111671918A (zh) 2011-06-08 2020-09-18 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
SG10201913683WA (en) 2011-06-21 2020-03-30 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP3366312A1 (en) 2011-06-23 2018-08-29 Alnylam Pharmaceuticals, Inc. Serpina 1 sirnas: compositions of matter and methods of treatment
JP2014526887A (ja) 2011-08-01 2014-10-09 アルナイラム ファーマシューティカルズ, インコーポレイテッド 造血幹細胞移植の成功率を改善する方法
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
CA3119789A1 (en) 2011-10-27 2013-05-02 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
CA2856116A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
CA3165769A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
WO2014047232A2 (en) 2012-09-21 2014-03-27 Cornell University C-rel inhibitors and uses thereof
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
PL2929031T4 (pl) 2012-12-05 2022-06-27 Alnylam Pharmaceuticals, Inc. Kompozycje iRNA PCSK9 i sposoby ich zastosowania
WO2014113089A2 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014112280A1 (ja) * 2013-01-17 2014-07-24 学校法人日本大学 油性組成物及び増粘又はゲル形成剤
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
WO2014184655A1 (en) 2013-02-07 2014-11-20 Olympic Seafood As Methods for using crustacean phospholipid-peptide-protein complexes
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
AU2014236305B2 (en) 2013-03-14 2019-01-17 Ethris Gmbh CFTR mRNA compositions and related methods and uses
ES2708561T3 (es) 2013-03-14 2019-04-10 Translate Bio Inc Métodos para la purificación de ARN mensajero
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR102605775B1 (ko) 2013-03-14 2023-11-29 알닐람 파마슈티칼스 인코포레이티드 보체 성분 C5 iRNA 조성물 및 그 이용 방법
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US10246708B2 (en) 2013-05-06 2019-04-02 Alnylam Pharmaceuticals, Inc. Dosages and methods for delivering lipid formulated nucleic acid molecules
CN110317810A (zh) 2013-05-22 2019-10-11 阿尔尼拉姆医药品有限公司 Tmprss6 irna组合物及其使用方法
KR20220154244A (ko) 2013-05-22 2022-11-21 알닐람 파마슈티칼스 인코포레이티드 SERPINA1 iRNA 조성물 및 이의 사용 방법
WO2014210031A1 (en) 2013-06-25 2014-12-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Proteomic biomarkers of sepsis in elderly patients
CN105793423A (zh) 2013-10-02 2016-07-20 阿尔尼拉姆医药品有限公司 用于抑制lect2基因表达的组合物和方法
JP6613227B2 (ja) 2013-10-04 2019-11-27 アルナイラム ファーマシューティカルズ, インコーポレイテッド Alas1遺伝子の発現を阻害する組成物および方法
CN106413811A (zh) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
JP6506749B2 (ja) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのmRNA療法
NZ718817A (en) 2013-10-22 2020-07-31 Massachusetts Inst Technology Lipid formulations for delivery of messenger rna
AU2014362262B2 (en) 2013-12-12 2021-05-13 Alnylam Pharmaceuticals, Inc. Complement component iRNA compositions and methods of use thereof
ES2895651T3 (es) 2013-12-19 2022-02-22 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
KR102389968B1 (ko) 2014-02-11 2022-04-25 알닐람 파마슈티칼스 인코포레이티드 케토헥소키나제(KHK) iRNA 조성물 및 그의 사용 방법
ES2750661T3 (es) 2014-04-25 2020-03-26 Translate Bio Inc Métodos para la purificación de ARN mensajero
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
EA201692370A1 (ru) 2014-05-22 2017-03-31 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
ES2750686T3 (es) 2014-05-30 2020-03-26 Translate Bio Inc Lípidos biodegradables para la administración de ácidos nucleicos
PE20171238A1 (es) 2014-06-24 2017-08-24 Shire Human Genetic Therapies Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US10342761B2 (en) 2014-07-16 2019-07-09 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP3188734A4 (en) 2014-09-02 2018-01-10 The Texas A&M University System Method of treating organophosphate intoxication
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2016061487A1 (en) 2014-10-17 2016-04-21 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
AU2015350120B2 (en) 2014-11-17 2021-05-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
EP3569711B1 (en) 2014-12-15 2021-02-03 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
JP2018510621A (ja) 2015-02-13 2018-04-19 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
US10745702B2 (en) 2015-04-08 2020-08-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
CN115927335A (zh) 2015-04-13 2023-04-07 阿尔尼拉姆医药品有限公司 类血管生成素3(ANGPTL3)iRNA组合物及其使用方法
BR112017021967A2 (pt) 2015-05-06 2018-07-31 Alnylam Pharmaceuticals Inc composições do fator xii (fator hageman) (f12), kallikrein b, plasma (fator fletcher) 1 (klkb1), e kininogen 1 (kng1) irna e métodos de uso dos mesmos
US9861597B2 (en) 2015-05-19 2018-01-09 Penn State Research Foundation Gluconate-based compositions as a neonate anticonvulsant
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
FI3310764T3 (fi) 2015-06-19 2023-07-18 Massachusetts Inst Technology Alkenyylillä substituoidut 2,5-piperatsiinidionit ja niiden käyttö koostumuksissa agenssin kuljettamiseksi subjektille tai soluun
CA3036409C (en) 2015-09-08 2023-07-11 Erik J. Sontheimer Dnase h activity of neisseria meningitidis cas9
EP3350328A1 (en) 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
WO2017048843A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
EP4424828A1 (en) 2015-12-07 2024-09-04 Genzyme Corporation Methods and compositions for treating a serpinc1-associated disorder
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
US10729690B2 (en) 2016-01-13 2020-08-04 University Of Massachusetts Antihelminthic medications for pathogenic nematodes
US10322171B2 (en) 2016-02-19 2019-06-18 The Board Of Regents Of The University Of Texas Systems Vaccine with reduced enhancement of viral infection
CN109152848B (zh) 2016-03-15 2022-12-09 马萨诸塞大学 抗-crispr化合物以及使用方法
US10213503B2 (en) 2016-05-19 2019-02-26 The Board Of Trustees Of The University Of Texas System Attenuated Burkholderia mallei strain which protects against pathogenic Burkholderia infections, vaccine containing and use thereof
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. 補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
TWI788312B (zh) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
SG10201913552UA (en) 2016-12-16 2020-03-30 Alnylam Pharmaceuticals Inc Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
US11241436B2 (en) 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
WO2018208547A1 (en) 2017-05-10 2018-11-15 University Of Massachusetts Bivalent dengue/hepatitis b vaccines
EP3624824B1 (en) 2017-05-16 2024-07-10 Translate Bio, Inc. Codon-optimized mrna encoding cftr for use in treating cystic fibrosis
US10590416B2 (en) 2017-07-06 2020-03-17 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
CA3069868A1 (en) 2017-07-13 2019-01-17 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
US11331319B2 (en) 2017-09-28 2022-05-17 University Of Massachusetts Combination treatment for neuropsychiatric disorders
EP3700965A1 (en) 2017-10-27 2020-09-02 Massachusetts Institute of Technology Poly (beta-amino esters) and uses thereof
US20200385719A1 (en) 2017-11-16 2020-12-10 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019103967A1 (en) 2017-11-22 2019-05-31 The Regents Of The University Of Michigan Compositions and methods for treating cancer
CA3086343A1 (en) 2017-12-18 2019-06-27 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
JP7381469B2 (ja) 2018-01-03 2023-11-15 ザ、ペン、ステート、リサーチ、ファウンデーション 新生児抗痙攣薬としてのグルコースオキシダーゼ組成物
JP2021522862A (ja) 2018-05-11 2021-09-02 アルファ アノマリック エスアエス 7’−5’−アルファ−アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート
MX2021000099A (es) * 2018-06-29 2021-03-25 Basf Se Sales de esteramina.
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス, インコーポレイテッド Ccr2及びcsf1rを標的とするためのオリゴヌクレオチド組成物ならびにその使用
EP3837367A1 (en) 2018-08-16 2021-06-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CN118421617A (zh) 2018-08-24 2024-08-02 川斯勒佰尔公司 用于纯化信使rna的方法
CA3117781A1 (en) 2018-10-26 2020-04-30 Massachusetts Institute Of Technology Polymer-lipids and compositions
JP2022542863A (ja) 2019-07-24 2022-10-07 ハー・ルンドベック・アクチエゼルスカベット 抗mGluR5抗体及びその使用
WO2021030522A1 (en) 2019-08-13 2021-02-18 Alnylam Pharmaceuticals, Inc. SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
BR112022003860A2 (pt) 2019-09-03 2022-08-16 Alnylam Pharmaceuticals Inc Composições e métodos para inibir a expressão do gene lect2
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
CN114728018B (zh) 2019-11-01 2024-07-19 阿尔尼拉姆医药品有限公司 亨廷顿(HTT)iRNA药剂组合物及其使用方法
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
US20230056569A1 (en) 2019-11-22 2023-02-23 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
WO2021119226A1 (en) 2019-12-13 2021-06-17 Alnylam Pharmaceuticals, Inc. Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
BR112022015770A2 (pt) 2020-02-10 2022-10-11 Alnylam Pharmaceuticals Inc Composições e métodos para silenciar a expressão de vegf-a
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
WO2021188611A1 (en) 2020-03-18 2021-09-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en) 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
WO2021202443A2 (en) 2020-03-30 2021-10-07 Alnylam Pharmaceucticals, Inc. Compositions and methods for silencing dnajc15 gene expression
IL297121A (en) 2020-04-06 2022-12-01 Alnylam Pharmaceuticals Inc Compositions and methods for silencing myoc expression
EP4133079A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing scn9a expression
EP4133077A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
EP4133076A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
JP2023523993A (ja) 2020-04-27 2023-06-08 アルナイラム ファーマシューティカルズ, インコーポレイテッド アポリポタンパク質E(ApoE)iRNA剤組成物およびその使用方法
WO2021237097A1 (en) 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
EP4162050A1 (en) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
WO2022066847A1 (en) 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
WO2022076291A1 (en) 2020-10-05 2022-04-14 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
AU2021365822A1 (en) 2020-10-21 2023-06-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en) 2020-10-23 2022-04-28 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
AU2021393417A1 (en) 2020-12-01 2023-06-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
IL304880A (en) 2021-02-12 2023-10-01 Alnylam Pharmaceuticals Inc Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-) associated neurodegenerative diseases
WO2022182864A1 (en) 2021-02-25 2022-09-01 Alnylam Pharmaceuticals, Inc. Prion protein (prnp) irna compositions and methods and methods of use thereof
EP4305169A1 (en) 2021-03-12 2024-01-17 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
MX2023011466A (es) 2021-03-29 2024-02-01 Alnylam Pharmaceuticals Inc Composiciones de agentes de ácido ribonucleico de interferencia (arni) de huntingtina (htt) y métodos de uso de estas.
JP2024522068A (ja) 2021-05-18 2024-06-11 アルナイラム ファーマシューティカルズ, インコーポレイテッド ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
BR112023025224A2 (pt) 2021-06-04 2024-02-27 Alnylam Pharmaceuticals Inc Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
WO2023283246A1 (en) 2021-07-09 2023-01-12 University Of Massachusetts Modular prime editor systems for genome engineering
TW202333748A (zh) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
WO2023076450A2 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2023085440A1 (ja) 2021-11-10 2023-05-19 公益財団法人東京都医学総合研究所 難治性ウイルス感染症の治療剤
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
CN114907243B (zh) * 2022-02-28 2023-10-27 东南大学 一种可离子化脂质、其组合物及应用
CN116120198B (zh) * 2022-03-21 2024-03-15 苏州科锐迈德生物医药科技有限公司 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN116354836A (zh) * 2022-03-25 2023-06-30 深圳市新合生物医疗科技有限公司 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
WO2023235501A1 (en) 2022-06-02 2023-12-07 University Of Massachusetts High fidelity nucleotide polymerase chimeric prime editor systems
WO2024025824A2 (en) 2022-07-25 2024-02-01 University Of Massachusetts Nucleic acid antisense oligomer readthrough of nonsense codons
TW202424193A (zh) 2022-09-15 2024-06-16 美商艾拉倫製藥股份有限公司 第13型17β-羥基類固醇去氫酶(HSD17B13)iRNA組成物及其使用方法
CN117820149A (zh) * 2023-12-29 2024-04-05 北京剂泰医药科技有限公司 可电离脂质化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5933222A (ja) * 1982-08-20 1984-02-23 Mitsui Toatsu Chem Inc 合成デオキシリボ核酸を有効成分とする抗腫瘍剤
JPS60104066A (ja) * 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
JPS61500439A (ja) * 1983-11-21 1986-03-13 リ−ジエンツ オヴ ザ ユニヴア−シテイ− オヴ ミネソタ 慢性的非経口ホルモン投与用緩衝化ポリオ−ル−ホルモン混合物
JPS61103824A (ja) * 1984-10-27 1986-05-22 Nippon Kayaku Co Ltd ポリリボイノシン酸・ポリリボシチヂル酸・ポリ−レ−リジン複合体の注射用製剤の新規調製法
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
GB2175588B (en) * 1985-04-15 1988-08-10 Toyo Jozo Kk Nucleoside-phospholipid conjugates
JP2527346B2 (ja) * 1987-01-27 1996-08-21 昭 梶 抗ウイルス剤
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US4882147A (en) * 1987-12-16 1989-11-21 The Research Foundation Of State University Of New York Novel polynucleotide analogs, methods for inhibiting nucleic acid polymerases and methods for inducing synthesis of interferon
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
ES2052066T3 (es) * 1988-10-31 1994-07-01 Sandoz Nutrition Ltd Mejoras en o relacionadas con compuestos organicos.
JPH03240795A (ja) * 1990-02-15 1991-10-28 Ajinomoto Co Inc 新規オリゴヌクレオチド誘導体及び抗ウイルス剤への使用
JP2604268B2 (ja) * 1990-04-09 1997-04-30 富士写真フイルム株式会社 ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
JPH04210921A (ja) * 1991-02-08 1992-08-03 Asahi Chem Ind Co Ltd 新規リン脂質・ヌクレオシド誘導体を有効成分とする抗腫瘍剤

Similar Documents

Publication Publication Date Title
RU95121693A (ru) Производные глицерина, средство для доставки лекарств (dds) и фармацевтическая композиция
RU95121696A (ru) Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты
KR960700997A (ko) 글리세롤 유도체, 디바이스 및 의약 조성물(glycerol derivative, device and pharmaceutical composition)
MX9204627A (es) Compuestos 1-acilpiperidina, procedimiento para su preparacion y composicion farmaceutica que los comprende.
ATE4903T1 (de) 1-, 6- und 2-substituierte 1-carba-2-penem-3carbons[ure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
DE20121305U1 (de) Nukleosid-Verbindungen
KR950031068A (ko) 골다공증의 복합 치료
ATE138647T1 (de) 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung als arzneimittel
EP0285706A1 (en) Medicament for the therapeutic treatment of alopecia
ATE147272T1 (de) Pharmazeutische zubereitungsformen
ATE15443T1 (de) Essbare, pharmazeutische zusammensetzungen und verfahren zur herstellung.
FI970634A0 (fi) Syklosporiinien uudet, suun kautta annettavat, koostumukseltaan yksinkertaiset valmistemuodot, joista biosaatavuus on hyvä, sekä menetelmä niiden valmistamiseksi
US4396597A (en) Process for the preparation of a sterile injectable physiologically acceptable solution of an X-ray contrast agent and solutions of the X-ray contrast agent and a buffer
KR890005034A (ko) 디카복실산-비스(3,5-디카바모일-2,4,6,-트리요오도아닐리드) 및 이를 함유하는 x-선 조영제
RU94044435A (ru) Производные амида витамина д, способы их получения, фармацевтическая композиция и способ лечения
RU2003134629A (ru) Соединения цефема
ATE100464T1 (de) Peptid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
CA2338854A1 (en) Nitric esters and nitrate salts of specific drugs
KR920003991A (ko) 비(鼻)투약용 칼시톤인을 함유하는 유제
RU2218334C2 (ru) Замещенные 1,2,3,4,5,6-гексагидро-2,6-метано-3-бензазоцин-10-олы и фармацевтическая композиция на их основе
KR900001675A (ko) 기관지확장 작용을 갖는 화합물
KR940014287A (ko) 아이오드화 벤조일 아세탈 및 케탈
DE69426908D1 (de) Derivate der Phosphonsäure, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
DE3866198D1 (de) Pharmazeutische zubereitung fuer die intrarektale verabreichung von calcitonin und daraus hergestellte einzeldosisformen.